Current Research Studies
Efficacy, safety, and pharmacokinetics of vericiguat in pediatric participants with heart failure due to left ventricular systolic dysfunction
VALOR
What is the goal of the study?
Phase 2/3 adaptive randomized, placebo-controlled, parallel-group, multisite, double-blind study of vericiguat in pediatric participants with HF due to LV systolic dysfunction consistent with dilated cardiomyopathy and NT-proBNP level between 500 and 6000 pg/mL within 30 days before randomization.
Who can participate in the study?
Please contact the study team listed below to learn more.